Inclusion Criteria: *Patients must meet all of the inclusion criteria at the time of screening*  Must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions:  Rheumatoid arthritis or adults previously diagnosed with Juvenile idiopathic arthritis (analyzed as a single category) Psoriatic arthritis (PsA), Ankylosing spondylitis (ASp), or other Spondyloarthritis (SpA) Must have completed the 2-dose regimen of either of the two mRNA COVID-19 vaccines more than 28 days previous to enrollment Must be scheduled for an additional dose of mRNA COVID-19 vaccination booster (or with plans to schedule booster) within the next 30 days Must have a cell phone capable of receiving text messages, and/or a personal email address Currently receiving one of the medications described in Table 1 Without any meaningful interruption or change in immunomodulatory therapy since the time of initial vaccine series to the time of study enrollment. Dose changes of immunomodulatory therapies are permitted, as are brief interruptions of < 2 weeks Must be 18 years of age or older Must live in the United States.  Exclusion Criteria:  • Already received a non-mRNA COVID-19 vaccine dose (J&J)  Any use in the past 90 days of a monoclonal antibody against COVID-19 (e.g., bamlanivimab, casirivimab, imdevimab) Any known contraindication to COVID-19 vaccination, including allergic reaction to prior COVID-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase) Known HIV/AIDS or any other immunodeficient condition Use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation) Currently receiving radiation or chemotherapy for any type of malignancy. Receipt of any immunization other than COVID-19 within two weeks prior to the COVID-19 vaccine supplemental dose Significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to < 1 year) Any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)